Pinned Tweet
It has been a bumpy year at personal level. As we head into #ASCO2023, thanks @GileadSciences for featuring my personal journey in Oncology. Special thanks to my Gilead team, all mentors/colleagues. We’re in this together to #endcancer #lcsm
Bilal Piperdi, Vice President of Clinical Research in Oncology, explains why he came to Gilead and how his Oncology team is helping to bring more life to people with lung cancer.
13
2,604
Bilal Piperdi retweeted
So many hot drops leading up to #ESMO26.
Not to be outdone by AZUR-1, CheckMate 8HW, or any of the other incredible IO breakthroughs, Chalabi comes out with the long-term NICHE-2 follow-up.
In a word? Perfect.
111 patients with locally advanced dMMR colon cancer. Just 6 weeks of neoadjuvant nivolumab/ipilimumab followed by surgery.
Zero recurrences. 100% overall survival at 5 years.
And remember, these weren’t all low-risk tumors. Many had high-risk stage III disease.
We’re curing patients with just weeks of immunotherapy.
Now, can we avoid the surgery altogether?
What a time to be treating GI cancers.
@TheGutOncLab @OncoAlert @Onco_Nexus
sciencedirect.com/science/ar…
Bilal Piperdi retweeted
2019: AstraZeneca made a multibillion-dollar bet on a novel Asia-developed drug called T-DXd. The rest is history.
2026: AstraZeneca made a multibillion-dollar bet on a novel Asia-developed drug called Ivonescimab.
History repeating itself?
astrazeneca.com/media-centre…
Bilal Piperdi retweeted
Two practice-informing trials at #ESMOBreast26 carry a broader lesson for oncology: sequencing #ADCs with the same payload class — here, a TOPO1 inhibitor — may not work simply by changing the target, linker, or PK.
BRE-354 from @ErikaHamilton9 @SarahCannonDocs and SATEEN from @PTarantinoMD @adawaksmd @DFCI_BreastOnc both speak to this important question.
This echoes what we have seen with PD-1 after PD-1 strategies: changing the partner drug does not necessarily overcome resistance to the same core mechanism. In RCC, two randomized phase III trials showed that this approach does not generally work:
TiNivo-2: shorturl.at/hP8AI
CONTACT-03: shorturl.at/litTw
with @montypal @motzermd @AlbigesL @BradMcG04 in @TheLancet
The biology of resistance matters. Mechanism matters. Payload matters.
@myESMO @ASCO @AACR @OncoAlert
Bilal Piperdi retweeted
I was curious about the most cited (non-Covid) clinical trial from the last 10 years — it's this one: 11,288 citations
Pembrolizumab beat chemotherapy in PDL1–positive non–small-cell lung cancer, dislodged it as the first-line treatment (and ended up doubling median survival)
Bilal Piperdi retweeted
In 1991, US cancer death rates hit an all-time high. Advances in early detection & treatment helped bring mortality rates down, averting 4.5 million deaths.
Tell your lawmakers to support cancer research funding: brnw.ch/21wXB4g
#SaveResearchStopCancer #ASCOAdvocacy
Bilal Piperdi retweeted
The country’s highest profile Democratic politicians spent the day valorizing Dick Cheney while Democratic voters were busy electing Zohran Mamdani.
Let that sink in.
Bilal Piperdi retweeted
60,000 white flags going up today on the National Mall, since November is Lung Cancer Awareness Month. Each flag represents two lives lost to #lungcancer. I'll share my story Wednesday at news conference, ahead of @LUNGevity's "Breathe Deep" event on Sat. Nov. 8 on the mall.
Bilal Piperdi retweeted
Review in JAMA on lung cancer in patients with no smoking history, who now make up about 20% of all new cases of lung cancer. The biology of these cancers is different, as is the treatment, but the gravity is the same. Read now at @JAMA_current.
jamanetwork.com/journals/jam…
Bilal Piperdi retweeted
Presented at #ESMO25:
In untreated, advanced triple-negative breast cancer, sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy (9.7 months vs. 6.9 months). Full ASCENT-03 phase 3 trial results: nej.md/4ncuUCV
@myESMO
2 NEJM and 1 Lancet simultaneous publication
#ESMO25 Presidential symposium #2 3/4 potentially practiced changing/informing phase 3 trials conducted in China. What a change in landscape👏👏
5
336
#ESMO25 Presidential symposium #2 3/4 potentially practiced changing/informing phase 3 trials conducted in China. What a change in landscape👏👏
Bilal Piperdi retweeted
#ESMO25 Many phase 3 trials reporting out! Need a simple way to track FDA #OncTwitter approvals? Share & bookmark this page. It's an excellent resource for busy clinicians, everyone in #cancer #drugdevelopment, & Boards prep. Below is just 1 month! #regulatory #MedTwitter 1/2
Early morning walk in Barcelona for Presidential Symposium #WCLC2025
2
380
Bilal Piperdi retweeted
Congratulations @BrendonStilesMD @BalazsHalmosMD and @MontefioreNYC team on winning the @IASLC Care Team Award. It is well deserved!
#WCLC25 #LCSM
Nice paper from France on Survival of Patients with Lung Adeno Dx. in 2000, 2010, and 2020 in a public hospitals. Huge impact of TKI and IO on survival! A lot more room to improve but importantly pts need access to these drugs globally!! @lcsmchat evidence.nejm.org/doi/full/1…
Bilal Piperdi retweeted
#GileadNews: In an open letter, Chairman and Chief Executive Officer Daniel O’Day discusses our just-approved #HIV prevention medication and its role in our fight to help end the epidemic: gilead.inc/3TuzsrI
Bilal Piperdi retweeted
🚨 🚨 🚨 🚨 Big news for all future J-1 physicians!
Program Directors from all over the nation have received an Email from ECFMG telling them that
“the U.S. Department of State has lifted the pause on new visa appointments, and J-1 physicians have been explicitly prioritized for visa interview scheduling”!
Congratulations everyone!
"This is more than just an update—it’s a reminder that your dedication is paying off, and the doors to your future in U.S. medicine are wide open!"
#MedTwitter #IMG #j1visa
Bilal Piperdi retweeted
#GileadNews: The FDA has approved our injectable HIV-1 prevention medication, making it the first and only twice-yearly #HIV prevention option in the U.S. This approval is helping to usher in the future of prevention as we work to help end the epidemic. gilead.inc/4e9KI6B







































